Posted in Melanoma
Posted by Geoff Beaty on 23 October 2021
Studies have shown that the gut microbiota could influence the response of melanoma to anti–PD-1 immunotherapy. It is known that only 30%-40% of melanoma patients respond to anti–PD-1 immunotherapy, so the researchers focused on the gut microbiota of adult male patients. For the study, which was funded by the National Institutes of Health and published in Science, Professor Zarour and a team of colleagues, including Dr Diwakar Davar, MD, a Medical Oncologist/haematologist at...
|Posted in:NewsEvidence Based ResearchCancerMelanoma|